Children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia now have a new reason to pay attention.

Outpatient monitoring of CAR T-cell therapy reduces healthcare resource utilization and hospital days without impacting 30-day mortality, finds ASCO study.

Researchers at the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute report that ...

CAR-T therapy is a highly specialized treatment that requires careful patient selection and close monitoring. Some patients ...

New preliminary clinical data presented at ISSCR 2026 evaluated an induced pluripotent stem cell (iPSC)-derived CAR T-cell ...

Data from EULAR 2026 show that next-generation CAR T- and NK cell platforms induce powerful, drug-free clinical remissions in patients with highly refractory rheumatic diseases.

Today at ISSCR 2026, new preliminary clinical data was presented evaluating an induced pluripotent stem cell (iPSC)-derived ...

A study led by a researcher based at King's College London and McMaster University in Canada reveals how CAR-T cell therapy, a treatment that engineers a patient's own immune cells to recognize and ...

Summary: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of liquid blood cancers by engineering a patient’s own immune cells to destroy malignant targets, replicating ...

Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You ...

Before starting cell therapy, patients need more than hope — they need a plan. Dr. Muhammad Tariq breaks down what to expect ...

Fate Therapeutics has seen improvements in 4 patients with treatment-resistant systemic sclerosis who were dosed with it | ...